FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Shashank Rohatagi

Research Profile

Concepts & Ideas

Procedures

Chemicals & Drugs

Phenomena

Metabolic Clearance Rate

Disorders

Asthma

Co-author Network

Publications

TOP 3
Thomas G Wells; Joseph R Sherbotie; SaeHeum Song; Janice E Sullivan; Douglas L Blowey; Jeffrey Blumer; Reinilde Heyrman; Shashank Rohatagi; Daniel E Salazar
Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.
Shashank Rohatagi; Minggao Shi; Michelle Green; Helen Kastrissios; Jeanne Mendell; Indravadan Patel; Daniel E Salazar
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
James B Moberly; Robert J Noveck; Shashank Rohatagi; Ching Hsu; Hamim Zahir; Kenneth E Truitt
Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Shashank Rohatagi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Thomas G Wells; Joseph R Sherbotie; SaeHeum Song; Janice E Sullivan; Douglas L Blowey; Jeffrey Blumer; Reinilde Heyrman; Shashank Rohatagi; Daniel E Salazar
Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.
Paediatric drugs 2012;14(6):401-9.
2012: Shashank Rohatagi; Minggao Shi; Michelle Green; Helen Kastrissios; Jeanne Mendell; Indravadan Patel; Daniel E Salazar
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Thrombosis and haemostasis 2012;108(5):887-95.
2012: James B Moberly; Robert J Noveck; Shashank Rohatagi; Ching Hsu; Hamim Zahir; Kenneth E Truitt
Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.
Journal of clinical pharmacology 2012;52(7):996-1006.
2012: Jeffrey S Riesmeyer; Shashank Rohatagi; Daniel E Salazar; David S Small; Govinda J Weerakkody; Rebecca E Wrishko; C Steven Ernest; Ying G Li; Junxiang Luo; Lan Ni; William L Macias
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.
Journal of clinical pharmacology 2012;52(6):789-97.
2012: Daniel E Salazar; Minggao Shi; SaeHeum Song; Masaya Tachibana; Simon Zhou; Elliott M Antman; Tomas S Bocanegra; Timothy J Carrothers; Bruce Dornseif; Robert P Giugliano; Michelle Green; Helen Kastrissios; Satoshi Kunitada; Jeanne Mendell; Indravadan Patel; Shashank Rohatagi
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Thrombosis and haemostasis 2012;107(5):925-36.
2012: Helen Kastrissios; Tatiana Khariton; Smita Kshirsagar; Donald E Mager; Timothy J Carrothers; Bahru Habtemariam; Joseph R Walker; Shashank Rohatagi
Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites.
Journal of clinical pharmacology 2012;52(3):404-15.
2012: D E Salazar; J Shi; S H Song; D R Wada; R Heyrman; Shashank Rohatagi; T J Carrothers
The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects.
Clinical pharmacology and therapeutics 2012;91(2):250-6.
2011: David S Small; Ying G Li; C Steven Ernest; John H April; Nagy A Farid; Christopher D Payne; Kenneth J Winters; Shashank Rohatagi; Lan Ni
Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.
Journal of clinical pharmacology 2011;51(3):321-32.
2010: Russ Wada; Shashank Rohatagi; David Small; Kenneth J Winters; Daniel E Salazar
Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes.
Journal of clinical pharmacology 2010;50(8):904-13.
2009: Shashank Rohatagi; Timothy J Carrothers; Jon Kuwabara-Wagg; Tatiana Khariton
Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
Journal of clinical pharmacology 2009;49(11):1284-96.
2009: Joseph R Walker; Karen Brown; Shashank Rohatagi; Mohinder S Bathala; Chao Xu; Prachi K Wickremasingha; Daniel E Salazar; Donald E Mager
Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol).
Journal of clinical pharmacology 2009;49(10):1185-95.
2009: Ying G Li; Lan Ni; John T Brandt; David S Small; Christopher D Payne; C Steven Ernest; Shashank Rohatagi; Nagy A Farid; Joseph A Jakubowski; Kenneth J Winters
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.
Platelets 2009;20(5):316-27.
2009: Rebecca E Wrishko; C Steven Ernest; David S Small; Ying G Li; Govinda J Weerakkody; Jeffrey R Riesmeyer; William L Macias; Shashank Rohatagi; Daniel Salazar; Elliott M Antman; Stephen D Wiviott; Eugene Braunwald; Lan Ni
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
Journal of clinical pharmacology 2009;49(8):984-98.
2009: Shashank Rohatagi; Hamim Zahir; James B Moberly; Kenneth E Truitt; Shin-ichi Inaba; Takaichi Shimozato; T J Carrothers
Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.
Journal of clinical pharmacology 2009;49(1):50-62.
2008: C Steven Ernest; David S Small; Shashank Rohatagi; Daniel Salazar; Lars Wallentin; Kenneth J Winters; Rebecca E Wrishko
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Journal of pharmacokinetics and pharmacodynamics 2008;35(6):593-618.
2008: Shashank Rohatagi; Timothy J Carrothers; Jinyan Jin; William J Jusko; Tatiana Khariton; Joseph Walker; Kenneth Truitt; Daniel E Salazar
Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.
Journal of clinical pharmacology 2008;48(12):1420-9.
2008: Shashank Rohatagi; James Lee; Magdy Shenouda; Stephen Haworth; Mohinder Singh Bathala; Mark Allison; Igor Rubets; Reinilde Heyrman; Robert Noveck; Daniel E Salazar
Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.
Journal of clinical pharmacology 2008;48(11):1309-22.
2008: Shashank Rohatagi; Helen Kastrissios; Kunihiro Sasahara; Kenneth Truitt; James B Moberly; Russell Wada; Daniel E Salazar
Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.
British journal of clinical pharmacology 2008;66(1):60-70.
2008: Shashank Rohatagi; Timothy J Carrothers; Smita Kshirsagar; Tatiana Khariton; James Lee; Daniel Salazar
Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil.
Journal of clinical pharmacology 2008;48(7):823-36.
2008: Ying Hong; Shashank Rohatagi; Bahru Habtemariam; Joseph R Walker; Sherwyn L Schwartz; Donald E Mager
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.
Journal of clinical pharmacology 2008;48(6):696-707.
2006: Zuyu Guo; Zheming Gu; Stanley R Howell; Kelly Chen; Shashank Rohatagi; Lining Cai; Jinn Wu; John Stuhler
Ciclesonide disposition and metabolism: pharmacokinetics, metabolism, and excretion in the mouse, rat, rabbit, and dog.
American journal of therapeutics 2006;13(6):490-501.
2006: Joe G P Lim; Bharti Shah; Shashank Rohatagi; Alex Bell
Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
American journal of therapeutics 2006;13(1):32-42.
2006: Anne Paccaly; Annke D Frick; Shashank Rohatagi; Jingli Liu; Umesh Shukla; Ronald Rosenburg; Markus Hinder; Bradford K Jensen
Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure.
Journal of clinical pharmacology 2006;46(1):37-44.
2005: William Eckelman; Shashank Rohatagi; Kenneth A Krohn; David R Vera
Are there lessons to be learned from drug development that will accelerate the use of molecular imaging probes in the clinic?
Nuclear medicine and biology 2005;32(7):657-62.
2005: Virginia Norris; Lee Choong; Duyen Tran; Zoe Corden; Malcolm Boyce; Hasan Arshad; Stephen Holgate; Brian O'Connor; Sylvaine Millet; Barry Miller; Shashank Rohatagi; Stephane Kirkesseli
Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.
The Journal of allergy and clinical immunology 2005;116(4):761-7.
2005: Stanley J Szefler; Shashank Rohatagi; James Williams; Mark Lloyd; Sudeep Kundu; Donald Banerji
Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma.
Chest 2005;128(3):1104-14.
2005: Shashank Rohatagi; Sriram Krishnaswami; Marc Pfister; Srikumar Sahasranaman
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model.
American journal of therapeutics 2005;12(5):385-97.
2005: Zuzana Diamant; J Kuperus; R Baan; K Nietzmann; S Millet; P Mendes; Barry Miller; Dilip Amin; Shashank Rohatagi; Peter J Sterk; Henk C Hoogsteden; Jan-Bas Prins
Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2005;35(8):1080-7.
2005: Shashank Rohatagi; Yongyi Luo; Liduo Shen; Zuyu Guo; Christina Schemm; Yongqing Huang; Kelly Chen; Michael David; Ruediger Nave; S Peter King
Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide.
American journal of therapeutics 2005;12(3):201-9.
2004: Bharti Shah; Shashank Rohatagi; Chandrasekhar Natarajan; Stephane Kirkesseli; Robert Baybutt; Bradford K Jensen
Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects.
American journal of therapeutics 2004;11(3):175-89.
2004: Shashank Rohatagi; Bharti Shah; Jie Zhang; Zhaopie Zeng; Stephane Kirkesseli; Bradford K Jensen
Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Journal of clinical pharmacology 2004;44(4):348-58.
2004: Shashank Rohatagi; Sunny Chapel; Stephane Kirkesseli; Stephen Newman; Jie Zhang; Dominique Paccaly; Linda Randall; H Wray; Sheree Wellington; Bharti Shah; Bradford K Jensen
Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler.
American journal of therapeutics 2004;11(2):103-13.
2004: Shashank Rohatagi; Sireesh Appajosyula; Hartmut Derendorf; Stanley J Szefler; Ruediger Nave; Karl Zech; Donald Banerji
Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective.
Journal of clinical pharmacology 2004;44(1):37-47.
2003: Bharti Shah; Bradford K Jensen; Jie Zhang; Thomas Hunt; Shashank Rohatagi
Effect of food on pharmacokinetics of an inhaled drug: a case study with a VLA-4 antagonist, HMR1031.
Journal of clinical pharmacology 2003;43(12):1341-9.
2003: Bharti Shah; Gary Emmons; Shashank Rohatagi; Nancy E Martin; Bradford K Jensen
Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
American journal of therapeutics 2003;10(5):356-62.
2003: Shashank Rohatagi; V Arya; Karl Zech; Ruediger Nave; Günther Hochhaus; Bradford K Jensen; JS Barrett
Population pharmacokinetics and pharmacodynamics of ciclesonide.
Journal of clinical pharmacology 2003;43(4):365-78.
2003: Shashank Rohatagi; Hartmut Derendorf; Karl Zech
Risk-benefit value of inhaled corticosteroids: a pharmacokinetic/pharmacodynamic perspective.
Chest 2003;123(3 Suppl):430S-1S.
2002: Hampel Frank; Michael Gillen; Shashank Rohatagi; Janet Lim; George George
A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis.
Journal of clinical pharmacology 2002;42(10):1097-104.
2001: Shashank Rohatagi; MS Gillen; M Aubeneau; C Jan; B Pandit; Bradford K Jensen; Gerald R Rhodes
Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.
International journal of clinical pharmacology and therapeutics 2001;39(3):126-34.
2001: Peter H Hirst; Gary R Pitcairn; J C Richards; Shashank Rohatagi; MS Gillen; Stephen P Newman
Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler.
Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine 2001;14(2):155-65.
2001: Gerald R Rhodes; Shashank Rohatagi; MS Gillen; F Deluccia; Donald Banerji; Philip Chaikin
In vitro and in vivo techniques used in drug development for evaluation of dose delivery of inhaled corticosteroids.
Journal of clinical pharmacology 2001;41(1):7-18.
2001: PN Zannikos; Shashank Rohatagi; Bradford K Jensen
Pharmacokinetic-pharmacodynamic modeling of the antilipolytic effects of an adenosine receptor agonist in healthy volunteers.
Journal of clinical pharmacology 2001;41(1):61-9.
2000: Philip Chaikin; Gerald R Rhodes; R Bruno; Shashank Rohatagi; C Natarajan
Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
Journal of clinical pharmacology 2000;40(12 Pt 2):1428-38.
2000: Domenick Argenti; S K Vaccaro; Bharti Shah; Shashank Rohatagi; Bradford K Jensen
Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodiesterase IV inhibitor.
International journal of clinical pharmacology and therapeutics 2000;38(12):588-94.
2000: PN Zannikos; Shashank Rohatagi; Bradford K Jensen; S L DePhillips; D Massignon; F Calic; M Sibille; Stephane Kirkesseli
Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers.
Journal of clinical pharmacology 2000;40(11):1245-56.
2000: Shashank Rohatagi; F Calic; Neasa Harding; Marie-Laure Ozoux; J P Bouriot; Stephane Kirkesseli; L DeLeij; Bradford K Jensen
Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients.
Journal of clinical pharmacology 2000;40(11):1211-26.
2000: PN Zannikos; Shashank Rohatagi; Bradford K Jensen; S L DePhillips; Gerald R Rhodes
Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Journal of clinical pharmacology 2000;40(10):1129-40.
1999: Shashank Rohatagi; Gerald R Rhodes; Philip Chaikin
Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids.
Journal of clinical pharmacology 1999;39(7):661-3.
1997: Shashank Rohatagi; JS Barrett; KE DeWitt; D Lessard; RJ Morales
Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Biopharmaceutics & drug disposition 1997;18(8):665-80.
1997: Shashank Rohatagi; Jürgen Barth; Helmut W Möllmann; Günther Hochhaus; A Soldner; C Möllmann; Hartmut Derendorf
Pharmacokinetics of methylprednisolone and prednisolone after single and multiple oral administration.
Journal of clinical pharmacology 1997;37(10):916-25.
1997: Shashank Rohatagi; JS Barrett; KE DeWitt; RJ Morales
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Biopharmaceutics & drug disposition 1997;18(7):567-84.
1997: Bernd Meibohm; Günther Hochhaus; Shashank Rohatagi; Helmut W Möllmann; Jürgen Barth; M Wagner; Michael Krieg; R Stöckmann; Hartmut Derendorf
Dependency of cortisol suppression on the administration time of inhaled corticosteroids.
Journal of clinical pharmacology 1997;37(8):704-10.
1997: Shashank Rohatagi; JS Barrett; W Sawyers; K Yu; RJ Morales
Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet.
American journal of therapeutics 1997;4(7-8):229-38.
1997: Shashank Rohatagi; S Kan; Hartmut Derendorf
Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration.
Die Pharmazie 1997;52(7):529-32.
1997: Shashank Rohatagi; JS Barrett
Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
American journal of therapeutics 1997;4(5-6):189-98.
1997: JS Barrett; T J Hochadel; RJ Morales; Shashank Rohatagi; KE DeWitt; S K Watson; J Darnow; A J Azzaro; AR DiSanto
Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Journal of clinical pharmacology 1997;37(3):238-47.
1997: Shashank Rohatagi; JS Barrett; L J McDonald; E M Morris; J Darnow; AR DiSanto
Selegiline percutaneous absorption in various species and metabolism by human skin.
Pharmaceutical research 1997;14(1):50-5.
1996: JS Barrett; KE DeWitt; T J Hochadel; RJ Morales; Shashank Rohatagi; S K Watson; AR DiSanto
Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly.
American journal of therapeutics 1996;3(10):688-98.
1996: Shashank Rohatagi; A Bye; C Falcoz; A E Mackie; Bernd Meibohm; Helmut W Möllmann; Hartmut Derendorf
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate.
Journal of clinical pharmacology 1996;36(10):938-41.
1996: JS Barrett; P Szego; Shashank Rohatagi; RJ Morales; K E De Witt; G Rajewski; J Ireland
Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Pharmaceutical research 1996;13(10):1535-40.
1996: Shashank Rohatagi; U Täuber; K Richter; Hartmut Derendorf
Pharmacokinetic/pharmacodynamic modeling of cortisol suppression after oral administration of fluocortolone.
Journal of clinical pharmacology 1996;36(4):311-4.
1996: Helmut W Möllmann; Günther Hochhaus; Shashank Rohatagi; Jürgen Barth; Hartmut Derendorf; Michael Krieg; Heike Weisser; Anja Clara Möllmann
Pharmacokinetics and pharmacodynamics of cloprednol.
International journal of clinical pharmacology and therapeutics 1996;34(1):1-5.
1995: Shashank Rohatagi; Günther Hochhaus; H Mollmann; Jürgen Barth; E Galia; M Erdmann; H Sourgens; Hartmut Derendorf
Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration.
Journal of clinical pharmacology 1995;35(12):1187-93.
1995: Shashank Rohatagi; Günther Hochhaus; Helmut W Möllmann; Jürgen Barth; Hartmut Derendorf
Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids.
Die Pharmazie 1995;50(9):610-3.
1995: Helmut W Möllmann; Günther Hochhaus; Shashank Rohatagi; Jürgen Barth; Hartmut Derendorf
Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone.
Pharmaceutical research 1995;12(7):1096-100.
1995: Hartmut Derendorf; Günther Hochhaus; Shashank Rohatagi; Helmut W Möllmann; Jürgen Barth; H Sourgens; M Erdmann
Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration.
Journal of clinical pharmacology 1995;35(3):302-5.